LENZ Therapeutics gains on NDA submission in China for presbyopia drug LNZ100

6 hours ago 1

Comments

LENZ Therapeutics (NASDAQ:LENZ) said Monday that CORXEL Pharmaceuticals has submitted the new drug application for LNZ100 to the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China.

LENZ Therapeutics (NASDAQ:LENZ), which licensed

Recommended For You

More Trending News

Read Entire Article